142 related articles for article (PubMed ID: 29731264)
1. Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations.
Tsikalakis S; Chatziandreou I; Michalopoulos NV; Theodoropoulos GE; Sakellariou S; Korkolopoulou P; Patsouris E; Saetta AA
Pathol Res Pract; 2018 Jun; 214(6):826-834. PubMed ID: 29731264
[TBL] [Abstract][Full Text] [Related]
2. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
3. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells.
Büneker C; Mohr A; Zwacka RM
Oncol Rep; 2009 May; 21(5):1289-95. PubMed ID: 19360306
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
[TBL] [Abstract][Full Text] [Related]
5. Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro.
McManus S; Chamoux E; Bisson M; Roux S
Apoptosis; 2012 Feb; 17(2):121-31. PubMed ID: 21972115
[TBL] [Abstract][Full Text] [Related]
6. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma.
Gaertner F; Krüger S; Röder C; Trauzold A; Röcken C; Kalthoff H
Histol Histopathol; 2019 May; 34(5):491-501. PubMed ID: 30375637
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis and mRNA expression of trail-receptors in human breast cancer.
Seitz S; Wassmuth P; Fischer J; Nothnagel A; Jandrig B; Schlag PM; Scherneck S
Int J Cancer; 2002 Nov; 102(2):117-28. PubMed ID: 12385006
[TBL] [Abstract][Full Text] [Related]
8. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.
Zhang XD; Franco A; Myers K; Gray C; Nguyen T; Hersey P
Cancer Res; 1999 Jun; 59(11):2747-53. PubMed ID: 10364001
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.
Kriegl L; Jung A; Horst D; Rizzani A; Jackstadt R; Hermeking H; Gallmeier E; Gerbes AL; Kirchner T; Göke B; De Toni EN
PLoS One; 2012; 7(12):e51654. PubMed ID: 23284732
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
Granci V; Bibeau F; Kramar A; Boissière-Michot F; Thézénas S; Thirion A; Gongora C; Martineau P; Del Rio M; Ychou M
Eur J Cancer; 2008 Oct; 44(15):2312-8. PubMed ID: 18755584
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients.
Salehi E; Vodjgani M; Massoud A; Keyhani A; Rajab A; Shafaghi B; Gheflati Z; Aboufazeli T
Iran J Immunol; 2007 Dec; 4(4):197-205. PubMed ID: 18057577
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
13. Tissue distribution of the death ligand TRAIL and its receptors.
Spierings DC; de Vries EG; Vellenga E; van den Heuvel FA; Koornstra JJ; Wesseling J; Hollema H; de Jong S
J Histochem Cytochem; 2004 Jun; 52(6):821-31. PubMed ID: 15150291
[TBL] [Abstract][Full Text] [Related]
14. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.
Koschny R; Krupp W; Xu LX; Mueller WC; Bauer M; Sinn P; Keller M; Koschny T; Walczak H; Bruckner T; Ganten TM; Holland H
Pathol Res Pract; 2015 Feb; 211(2):109-16. PubMed ID: 25481563
[TBL] [Abstract][Full Text] [Related]
15. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.
Sträter J; Hinz U; Walczak H; Mechtersheimer G; Koretz K; Herfarth C; Möller P; Lehnert T
Clin Cancer Res; 2002 Dec; 8(12):3734-40. PubMed ID: 12473583
[TBL] [Abstract][Full Text] [Related]
16. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
17. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
18. TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.
Oikonomou E; Kosmidou V; Katseli A; Kothonidis K; Mourtzoukou D; Kontogeorgos G; Andera L; Zografos G; Pintzas A
Int J Cancer; 2009 Nov; 125(9):2127-35. PubMed ID: 19637313
[TBL] [Abstract][Full Text] [Related]
19. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
